今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-049508 Act: 34 Size: 66 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-048735 Act: 34 Size: 113 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-048737 Act: 34 Size: 46 KB 网页链接
$Trident(TDAC)$ S-4/A [Amend] Registration of securities, business combinations Accession Number: 0001213900-21-048657 Act: 33 Size: 17 MB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-047345 Act: 34 Size: 65 KB 网页链接
$Trident(TDAC)$ 8-K Current report, item 8.01 Accession Number: 0001213900-21-046242 Act: 34 Size: 284 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-046244 Act: 34 Size: 41 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-044798 Act: 34 Size: 7 MB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-044802 Act: 34 Size: 7 MB 网页链接
$Trident(TDAC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-21-043067 Act: 34 Size: 3 MB 网页链接